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Abstract: Dendritic cells (DCs) are commonly generated from bone marrow (BM) progenitor cells 
with granulocyte-macrophage colony-stimulating factor (GM-CSF) alone or in combination with 
interleukin 4 (IL-4). These cells are often harvested post day 5, when they acquire maturation 
markers and can stimulate T cells. Apart from DCs, myeloid derived suppressor cells (MDSCs) are 
also found within these cultures. However, little is known about the functional characteristics of 
DCs and MDSCs before day 5. Herein, using a murine model, it is shown that early DCs and MDSCs, 
even in cultures with GM-CSF alone, upregulate fully maturation and activation surface molecules 
in response to the toll-like receptor 4 (TLR4) ligand lipopolysaccharide (LPS) stimulation. Despite 
initially displaying lower marker expression levels, these cells efficiently induced T cell stimulation 
and cytokine production. Interestingly, Gr-1int MDSCs increased their T cell co-stimulatory activity 
upon TLR4 stimulation. Additionally, early DCs and MDSCs exhibited differential endocytic 
capacity for viral sized nanoparticles and bacterial sized microparticles. DCs internalized both 
particle sizes, whilst MDSCs only internalized the larger microparticles, with reduced endocytic 
activity over time in the culture. These findings have unveiled an important role for the rapid 
initiation of productive immunity by GM-CSF, with promising implications for future vaccine and 
DC immunotherapy developments. 
Keywords: granulocyte-macrophage colony-stimulating factor; GM-CSF; dendritic cells; myeloid 
derived suppressor cells; MDSCs; bone marrow culture 
 
1. Introduction 
The bone marrow (BM) is the primary source of key immunostimulatory antigen presenting cells 
(APC) such as dendritic cells (DCs), as well as innate regulatory cells such as myeloid derived 
suppressor cells (MDSCs). DCs link the innate and adaptive immune system by recognizing 
pathogens and presenting peptide epitopes to T cells. They are the most efficient APC, able to prime 
naïve T cells. Although scarce in number, DCs are strategically located in most tissue niches, which 
allows them to interact proficiently with T cells and B cells [1]. DCs all have in common the ability to 
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recognize pathogens, capture and process antigens, and present them to T cells to activate the 
adaptive immune response [1–3]. This process requires three signals: recognition of the peptide 
epitope in the major histocompatibility complex (MHC) by the T cell; expression of co-stimulatory 
molecules; and secretion of cytokines. Immature DCs typically express low to moderate levels of the 
co-stimulatory molecules CD80 (B7-1), CD86 (B7-2), CD40 and MHC class I and II [2]. When fully 
activated they are capable of secreting T helper (Th)1 polarizing cytokines such as interleukin (IL)-
12, tumor necrosis factor (TNF) and interferon (IFN)-γ [4,5], and Th2 polarizing cytokines such as IL-
4, IL-5, IL-6 and IL-13 [6]. 
Conversely, MDSCs are a heterogeneous population of early myeloid progenitors which can 
exert immuno-regulatory functions, and consist of immature granulocytes, macrophages and DCs 
[1–3]. These cells consistently express the surface integrin CD11b as well as varying levels of the 
myeloid lineage differentiation antigen, Gr-1 (Ly6G/Ly6C) [3–5]. MDSCs can be divided into two 
subsets: monocytic and granulocytic MDSCs. Several murine studies have identified additional 
markers such as F4/80, intracellular adhesion molecule 1 (ICAM-1) and  C-C chemokine receptor 2 
(CCR2) that are also expressed on MDSCs [3,6,7]. MDSCs, most prominently monocytic MDSCs, 
inhibit T cell activation and prevent antigen presentation of APCs by producing nitric oxide, reactive 
oxygen species (ROS) and arginase-1 [8,9]. 
The hematopoietic growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF) 
has been commonly used to generate both DCs and MDSCs from BM cells in vitro. Administered 
intravenously in humans it is also capable of attracting monocytes, DC and MDSC precursors into 
circulation, where they can be captured to further expand them for diverse applications, for example, 
re-infusible DC-based vaccine therapies [10]. GM-CSF is a pro-inflammatory cytokine thought to be 
secreted by lymphocytes involved in the development of myeloid cells. GM-CSF is implicated in 
inflammatory conditions, due to its upregulation and ability to attract macrophages and direct 
monocytes into inflammatory type DCs during infection [11,12]. There have also been clinical benefits 
for some autoimmune and inflammatory conditions by blocking GM-CSF and/or the GM-CSF 
receptor [13]. 
GM-CSF BM cultures are heterogenous and include both functional DCs and macrophages with 
distinct marker expression and capabilities [14,15]. Other myeloid and granulocytic cell types may 
also be present in these cultures. BM-derived DCs grown in GM-CSF are highly phagocytic and have 
a survival advantage compared to steady state cells grown using fms-like tyrosine kinase 3 (FLT-3) 
ligand [16]. Lipopolysaccharide (LPS) has also been shown to increase the survival of GM-CSF 
derived DCs, mediated by the phosphoinositide 3-kinase (PI3K) pathway [17]. 
The functionality of BM cell derived DCs or MDSCs in early GM-CSF stage cultures has not been 
fully defined. Previously it has been shown that early stage (Day 3 or 4) GM-CSF derived DCs are 
functional, though their cytokine secretion and T cell stimulatory capacity are reduced in the presence 
of cancer cells [18]. Recent studies also suggest that the induction of mature inflammatory DCs by 
GM-CSF may also inadvertently induce MDSCs, thus potentially impeding the efficacy of DC-based 
vaccines and immunotherapies. This led us to investigate the properties and functions of DCs and 
MDSCs generated in early GM-CSF derived BM cultures (Day 3–5). Herein we use a murine model 
to characterize these cells and show that early DCs and MDSCs are capable of rapidly responding to 
pro-inflammatory stimuli to activate and undergo maturation, expressing high levels of T cell co-
stimulatory molecules, whilst retaining endocytic properties. Importantly, early DCs post LPS 
maturation efficiently induce T cell proliferation, whereas early culture monocytic MDSCs do not 
induce T cell proliferation unless in the presence of the T cell stimulation molecules anti-CD3 and 
anti-CD28. Together these data shed new insight into the biology of DCs and MDSCs and suggest 
that these cell types are differentially regulated via the toll-like receptor 4 (TLR4) receptor to promote 
an overall pro-inflammatory environment. 
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2. Materials and Methods  
2.1. Animals 
C57BL/6 mice 6–8 weeks old were obtained from the Precinct Animal Centre (PAC) at the Alfred 
Medical Research and Educational Precinct (AMREP) (Melbourne, VIC, Australia). BALB/c mice aged 
between 6–8 weeks were obtained from Monash Animal Services (Melbourne, VIC, Australia). All 
experiments had ethics approval by the Animal Ethics Committee of AMREP under ethics numbers 
E/1032/2010/M, E/1052/2011/M and E/1130/2011/M. 
2.2. Isolation of BM Cells from Mice 
Mice were culled by CO2 asphyxiation. The mice were sprayed with 70% v/v ethanol to prevent 
bacterial contamination, and skin removed to expose the legs. Femur and tibia of both legs were 
extracted, and muscles removed. The bones were then soaked in 70% v/v ethanol for 1 min to ensure 
aseptic conditions. Bones were removed from ethanol and thoroughly washed before being moved 
to a fresh tube of sterile RPMI (supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 
20 mM HEPES, 0.1 mM 2 mercaptoethanol and 100 units/mL penicillin and 100 μg of streptomycin; 
complete media; CM). Both ends of each bone were carefully cut off to expose the BM. A 3 mL syringe 
with 25-gauge needle filled with CM was used to flush each bone to dislodge the BM. The cells were 
then disaggregated with a 1 mL pipette and filtered through a cell strainer (100 μm, Millipore, 
Billerica, MA, USA) into a 10 mL centrifuge tube. The cells were centrifuged at 1400 rpm for 5 min at 
room temperature. The supernatant was carefully removed, and BM cells (with erythrocytes) were 
re-suspended in 1 mL of Ammonium-Chloride-Potassium (ACK) lysis buffer for 1 min to lyse 
erythrocytes. Lysis buffer was diluted with 9 mL of CM and centrifuged again at 1400 rpm for 5 min 
at room temperature. The supernatant was removed carefully and the BM cells (without erythrocytes) 
were re-suspended in 10 mL of CM. 
2.3. GM-CSF Derived DC Culture 
The concentration of BM cells was adjusted to 5 × 105 cells/mL in CM. GM-CSF (PeproTech, 
Rocky Hill, NJ, USA) was added to the cell suspension at a final concentration of 10 ng/mL. Where 
stated, IL-4 (PeproTech, Rocky Hill, NJ, USA) was also added to the cultures at a final concentration 
of 5 ng/mL. BM cells were cultured in 24-well plates in 1 mL of CM with GM-CSF or GM-CSF + IL-4 
and incubated at 37 °C in 5% CO2. Cells were harvested by gentle resuspension on either day 3, 4 or 
5 unless otherwise stated. To harvest the cells, the plates were centrifuged at 1400 rpm for 5 min at 4 
°C. The supernatant was collected, and cells were re-suspended in phosphate buffered saline (PBS) 
and prepared for cell surface staining. 
2.4. DC Activation by Lipopolysaccharide 
Where indicated, cells on culture days 3, 4 or 5 were co-cultured with or without LPS (1 μg/mL, 
derived from Escherichia coli; 0111:B4, Sigma-Aldrich, Louis, MO, USA) and incubated a further 24 
h at 37 °C in 5% humid CO2 atmosphere. After 24 h, the plates were centrifuged, the supernatants 
were collected, and the cells harvested by gentle resuspension, for analysis by flow cytometry. 
2.5. Preparation and Incubation of Fluorescent Particles in BM Culture 
AF488-labelled carboxylate-modified polystyrene microspheres (0.04 μm (F8795, 5% solids in 
water, Lot # 41892A, and 0.5 μm carboxylate-modified polystyrene microspheres F8813, 2% solids in 
water + azide, Lot # 23115W, Invitrogen-Molecular Probes, Carlsbad CA, USA) were dialyzed in 
MilliQ water overnight and sonicated for 15 min to reduce aggregation before using. 40 nm 
fluorescent particles (8 × 104 particles/cell) and 500 nm fluorescent particles (51.2 particles/cell) were 
diluted in CM and added into the culture for 1 h before the cells were harvested by gently 
resuspending the culture. The particle uptake by cultured cells was analyzed by flow cytometry, 
measuring the intensity of the AF488 stain. 
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2.6. Fluorochrome-Conjugated Antibody Cocktail Preparation and Cell Surface Staining 
All Fluorochrome-conjugated antibodies were titrated beforehand to determine optimal 
dilutions for detection by flow cytometry. The cells were harvested and stained with a combination 
of fluorochrome-conjugated antibodies (Table 1). Dead cells were discriminated using the 
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen, Life Technologies, Carlsbad, CA, USA). 
Antibodies were prepared in flow cytometry staining buffer (PBS + 2% v/v FBS) and cells were stained 
for 20 min on ice in the dark. After incubation, the cells were washed with staining buffer and 
centrifuged at 1400 rpm, at 4 °C for 5 min. The supernatant was carefully removed, and the cells were 
re-suspended in 100 μL of PBS/1% v/v paraformaldehyde. Samples were acquired with the LSRII (BD 
Biosciences, Franklin Lakes, NJ, USA) at the AMREP Flow Cytometry Core Facility (AMREP, 
Melbourne, Victoria, Australia). The data were analyzed using FlowJo Flow Cytometry Analysis 
Software (TreeStar Inc, Ashland, OR, USA). Cell clumps, dead cells and debris were removed during 
analysis on basis of the forward scatter/side scatter (FSC/SSC) and the Fixable Aqua Dead Cell Stain 
Kit to isolate live DCs; the percentage of live cells and the mean fluorescence intensity (MFI) and/or 
the percentage of marker expression were measured. 
Table 1. List of flow cytometry antibodies. 
Antibody Clone Fluorophore Company Catalogue Number 
B220 RA3-6B2 FITC BD Biosciences 553088 
B7H1 MIH5 PE BD Biosciences 557495 
c-kit 2B8 FITC BD Biosciences 553354 
CCR4 2G12 PECy7 BioLegend 131214 
CCR5 HM-CCR5 APC BioLegend 107011 
CCR7 4B12 PerCP Cy5.5 eBioscience 45-1971-82 
CD103 M290 PE BD Biosciences 557495 
CD11b M1/70 PE BD Biosciences 553311 
CD11b M1/70 PECy7 BD Biosciences 552850 
CD11c HL3 V450 BD Biosciences 560521 
CD14 rmC5-3 FITC BD Biosciences 553739 
CD172a P84 APC BD Biosciences 560106 
CD205 205yekta PECy7 BD Biosciences 25-2051-41 
CD205 NLDC-145 Biotin Cederlane CL89145B 
CD24 M1/69 PECy7 BD Biosciences 560536 
CD3 17A2 FITC BD Biosciences 555274 
CD3 500A2 AlexaFluor 700 BD Biosciences 557984 
CD31 MEC13.3 APC BD Biosciences 551262 
CD4 GK1.5 PE BD Biosciences 557308 
CD4 RM4-5 PerCP BD Biosciences 553052 
CD40 3/23 FITC BD Biosciences 553791 
CD44 IM7 Biotin BD Biosciences 553132 
CD62L MEL-14 FITC BD Biosciences 553150 
CD80 16-10A1 Biotin BD Biosciences 553767 
CD86 GL1 PE BD Biosciences 553692 
CD8a 53-6.7 PE BD Biosciences 553033 
CD8a 53-6.7 PerCP BD Biosciences 553036 
CD8a 53-6.7 APC BD Biosciences 553035 
F4/80 BM8 PE eBioscience 12-4801-80 
Gr-1 RB6-8C5 PerCP Cy5.5 BD Biosciences 552093 
Gr-1 RB6-8C5 Biotin BD Biosciences 553125 
IL-4Ra mIL4R-M1 PE BD Biosciences 561695 
MHCI class II M5/114.15.2 APCCy7 BD Biosciences 47-5321-80 
NK1.1 PK136 FITC eBioscience 12-5941-83 
Sca-1 D7 PE-Cy7 BD Biosciences 558162 
Streptavidin  AlexaFluor 700 Invitrogen S21383 
Streptavidin  APC BD Biosciences 554067 
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Streptavidin  APCCy7 eBioscience 47-4317-82 
Streptavidin  FITC BD Biosciences 554060 
Streptavidin  PE BD Biosciences 554061 
2.7. T Cell Purification 
Splenocytes from naïve BALB/c mice were harvested and incubated with ACK lysis buffer for 3 
min at RT to remove erythrocytes. T cells from splenocytes were isolated based on the manufacturer’s 
instructions using the MACS® Pan-T cells isolation kit (Miltenyi Biotec, Bergisch Gladbach, 
Germany). In brief, remaining cells were washed and incubated with a cocktail of biotin-conjugated 
antibodies against CD11b, CD11c, CD19, CD45R (B220), CD49b (DX5), CD105, MHCII, and Ter-119 
for 10 min on ice and further incubated with anti-biotin magnetic beads for 15 min at 4 °C. The 
isolation of unlabeled T cells was achieved by depletion of magnetically labelled cells.  
2.8. Mixed Leukocyte Reaction Assay 
To evaluate the T cell stimulatory capacity of DCs derived from GM-CSF BM cultures at day 3 
or 4, cultured cells were either left un-stimulated or stimulated with LPS and incubated for another 
24 h at 37 °C in 5% humid CO2 atmosphere before they were harvested and stained with either anti-
CD11c V450 (HL3), Gr-1 PerCP Cy5.5 or biotin Gr-1 (RB6-8C5)-Streptavidin-AlexaFluor 700 for 20 
min on ice in the dark. The cells were then washed and re-suspended in PBS with 2% v/v FBS, 0.01 M 
of EDTA at a concentration of 107 cells/mL and sorted with a cell sorter (BD Influx, BD Biosciences, 
Franklin Lakes, NJ, USA) at the AMREP Flow Cytometry Core Facility. DCs, granulocytic MDSCs 
and monocytic MDSCs were sorted based on CD11c+ Gr-1-, CD11c- Gr-1hi and CD11c- Gr-1int 
expressions, respectively. Sorted BALB/c T cells (105 cells) were stained with CellTrace™ 
carboxyfluorescein succinimidyl ester (CFSE) cell proliferation kit, as per manufacturer’s 
instructions, (Molecular Probes, Eugene, OR, USA) and seeded into 96 well U-bottom plates with the 
sorted cells (3 × 103 cells/well) in triplicates and incubated for three days at 37 °C in 5% humid CO2 
atmosphere. T cell proliferation was analyzed by measuring the MFI of CFSE via flow cytometry 
using the LSRII. 
2.9. T Cell Co-Stimulation Assay 
To assess the ability of cells isolated from day 3 or 4 GM-CSF derived BM cultures to induce T 
cell proliferation in the presence of an added stimulus, the cells were either left un-stimulated or 
stimulated with LPS for 24 h before they were harvested and sorted as described above. Sorted 
BALB/c T cells (105 cells) were stained with CellTrace™ CFSE cell proliferation kit and seeded with 
sorted cultured BM cells (3 × 103 cells). Soluble anti-CD3 (5 μg/mL) and anti-CD28 (5 μg/mL) (anti-
CD3/28, eBioscience, Inc, San Diego, CA, USA) were added and the culture was incubated for three 
days at 37 °C in 5% humid CO2 atmosphere. T cell proliferation was analyzed by flow cytometry 
using the LSRII. 
2.10. Cytokine Detection 
To detect and quantify cytokines secreted by the cultured BM cells, supernatants from GM-CSF 
derived BM cultures, either un-stimulated or stimulated with LPS (1 μg/mL), incubated for 24 h at 37 
°C in 5% humid CO2 atmosphere, were collected. Supernatants were analyzed using a cytometric 
bead array (CBA) inflammation kit (BD Biosciences, Franklin Lakes, NJ, USA), which included the 
cytokines IL-6, IL-10, monocyte chemoattractant protein 1 (MCP-1), and TNF. Preparation of the 
supernatants was performed following the manufacturer’s instructions. Briefly, for the CBA 
inflammation kit, 50 μL of either culture supernatant or standard cytokine solutions (0–5000 pg/mL) 
were incubated with 50 μL of cytokine capture beads and PE detection reagent for 2 h. Samples were 
acquired with the LSRII according to the CBA setup instructions in the kit. A minimum of 400 
events/cytokine was acquired for each sample. Standard cytokine solutions included in the 
inflammation kit and flexsets were used to plot out the standard curves and quantitative analysis of 
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cytokines was done using the FCAP Array software (Soft Flow Inc, St. Louis Park, MN, USA) based 
on the level of MFI. 
2.11. Statistical Analyses 
The data generated are shown as mean ± standard deviation (SD). All values were graphed and 
analyzed for statistical significance using Prism (GraphPad Software, Inc., San Diego, CA, USA). 
Student’s T-test was performed on two normally distributed experimental groups. For three or more 
experimental groups at a single time-point, one-way ANOVA with Tukey–Kramer multiple 
comparison tests was used if the data were normalized; if the data were not normalized, Kruskal–
Wallis test with Dunnett’s multiple comparison test was used. Two-way ANOVA with Bonferroni 
post-tests was used for three or more experimental groups at two or more time-points. Statistical 
significance was indicated by the p-value (* denotes p < 0.05; ** denote p < 0.01, *** denote p < 0.001). 
3. Results 
3.1. GM-CSF Induces an Early Surge in DC Generation without Inducing Expression of Activation Markers 
in BM Cultures 
In vitro DCs are generated from BM with various cytokine combinations such as GM-CSF, GM-
CSF + IL-4 or FLT-3L among others over a period of 5–9 days [19–21]. Despite the wide range of 
possible cytokine combinations available for DC generation, GM-CSF remains the most used 
cytokine. Although these cultures have been widely studied for their immunogenicity, little is known 
about the DCs or other myeloid cells present at the earlier time-points (days 3–5) in these cultures.  
The generation of in vitro DCs (characterized by surface expression of CD11c) from BM was 
systematically investigated by culturing murine BM cells for up to 7 days with GM-CSF alone or with 
GM-CSF + IL-4, monitoring the proportion of DCs daily using flow cytometry, measuring surface 
expression of CD11c. DC generation in GM-CSF cultures peaked and plateaued on day 5, while DC 
generation in GM-CSF + IL-4 cultures was slower and steadily continued to increase from days 3 to 
7 (Figure 1A). By day 7 both cultures contained about 60% DCs (CD11c+ cells, Figure 1A). Expression 
of molecules associated with a mature DC phenotype (CD40, CD80, CD86 and MHCII) were 
significantly lower on DCs generated in GM-CSF cultures when compared to GM-CSF + IL-4 cultures, 
even though we observed a gradual increase in expression of these molecules from days 4 to 7 (Figure 
1B). These results suggest that GM-CSF derived BM cultures can rapidly generate DC-like cells in 
culture with a more immature phenotype then DCs generated from GM-CSF + IL-4 cultures. 
3.2. Phenotype of GM-CSF Cultured Cells Yield Conventional DCs, Granulocytic Gr-1hi and Monocytic Gr-
1int MDSCs 
The cells isolated from the BM cultures generated using either GM-CSF alone or GM-CSF + IL-4 
were tested for differential expression of surface makers by determining the MFI within the CD11c+ 
population (Table 2). These GM-CSF derived DCs expressed lower levels of activation markers CD80 
(751.3 ± 10.79), CD86 (991 ± 26.96), MHCII (2052 ± 248.6) than their GM-CSF + IL-4 counterparts (CD80, 
1368 ± 13.5; CD86, 3229 ± 427; MHCII 12,634 ± 452.3) (Table 2). As expected, DCs derived from either 
culture, GM-CSF or GM-SCF + IL-4, exhibit a conventional DC phenotype, expressing CD11b but not 
B220, CD4 or CD8 (Figure 2). The DCs also expressed high levels of CD24 and CD44, which are 
associated with regulating T cell functions [22,23]. Based on the observations above, it can be 
postulated that GM-CSF derived DCs are conventional myeloid DCs that are less mature but may 
still be able to regulate T cell functions. 
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Figure 1. GM-CSF induces generation of DCs with lower activation marker expression in BM cultures 
compared to GM-CSF + IL-4. DCs (CD11c+ cells) generated from murine BM with GM-CSF (10 ng/mL) 
(black circles) or GM-CSF (10 ng/mL) + IL-4 (5 ng/mL) (white squares) from days 1–7 were evaluated 
for (A) the percentage of DCs generated and (B) the expression of CD40, CD80, CD86 and MHCII on 
the DCs. Results shown are from three mice, two-way ANOVA was used to compare both cultures at 
each time-point. Results displayed as mean +/− SD. * p < 0.05, ** p < 0.01, *** p < 0.001. 
Table 2. Comparison between the expression levels of phenotypic markers, chemokine receptors and 
activation markers on CD11c+ cells. 
Surface Markers GM-CSF DCs GM-CSF + IL-4 DCs p-Value Significance Mean MFI ± SD Mean MFI ± SD 
CD11b 14,969 ± 2668 4072 ± 473.1 0.0233 * 
CD44 75,858 ± 5882 52,938 ± 3483 0.0038 ** 
CD80 751.3 ± 10.79 1368 ± 13.5 <0.0001 *** 
CD86 991 ± 26.96 3229 ± 427 0.0114 * 
CD103 4933 ± 253.2 2444 ± 153.3 0.0029 ** 
CD172α 1943 ± 65.59 1599 ± 113.4 0.0098 ** 
F4/80 1499 ± 124.2 733.3 ± 48.68 0.0049 ** 
MHCII 2052 ± 248.6 12,634 ± 452.3 0.0004 *** 
Sca-1 3499 ± 339.2 2892 ± 278.9 0.007 ** 
 Results shown are from three mice. Unpaired students T test was used to compare groups. Results 
displayed as mean +/− SD. * p < 0.05, ** p < 0.01, *** p < 0.001. DCs, dendritic cells; MFI, Mean 
fluorescence intensity; SD, standard deviation. 
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Figure 2. The phenotype of cells from GM-CSF treated BM cultures is consistent with the presence of 
DCs. Live cells from GM-CSF derived BM culture were characterized on day 3. Cells generated from 
BM with GM-CSF (10 ng/mL) (solid line) or GM-CSF (10 ng/mL) + IL-4 (5 ng/mL) (dotted line) were 
characterized with a panel of phenotypic markers, chemokine receptors and activation markers. The 
shaded grey area represents unstained control cells. Results shown are representative of three mice. 
Within these cultures there were also a population of GM-CSF derived MDSCs identified. Upon 
analysis of GM-CSF derived Gr-1hi and Gr-1int MDSCs, they were found to have distinct morphologies 
(Supplementary Figure S1 and Figure S2) and growth patterns over time (Figure 3). Gr-1hi and Gr-1int 
MDSCs express high levels of CD11b (MFI 3827 ± 402.94), but not CD11c (MFI 31.27 ± 0.9), as well as 
low levels of other lineage markers such as CD62L (neutrophilic marker) (MFI 1157.33 ± 60.48), 
CD172α (MFI 523 ± 15.13) and F4/80 (myeloid markers) (MFI 533.33 ± 39.2) (Figure 4). Some MDSCs 
also expressed low levels of stem cell markers, c-kit (MFI 1126.67 ± 159.09) and Sca-1 (MFI 559.33 ± 
27.79), suggesting that they are not just early-phase hematopoietic stem cells HSCs. The expression 
of these markers has been observed previously on MDSCs detected in tumor-bearing mice and cancer 
patients, suggesting that these cells are indeed the in vitro equivalents of the MDSCs found in the 
tumor microenvironment [6,24]. Furthermore, these MDSCs exhibit low levels of the activation 
markers CD80 (MFI 976.33 ± 93), CD86 (MFI 876.67 ± 37.63) and MHCII (MFI 478.67 ± 4.51). Apart 
from the different levels of Gr-1 expression (Gr-1hi, MFI 7071.33 ± 215.93; Gr-1int, MFI 820 ± 33.81), it 
was not possible to distinguish the two populations of MDSCs based on any other markers. There 
was also no detectable difference between the MDSCs generated from GM-CSF and GM-CSF + IL-4 
cultures. 
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Figure 3. GM-CSF and GM-CSF + IL-4 cultures induce the generation of two subsets of MDSC. MDSCs 
(CD11c-, CD11b+, Gr-1+ cells) generated from murine BM with GM-CSF (10 ng/mL) (closed triangles) 
or GM-CSF (10 ng/mL) + IL-4 (5 ng/mL) (open triangles) from days 1-7. Cells were assessed for the 
percentage of (A) Gr-1hi MDSCs and (B) Gr-1int MDSCs generated within CD11c-, CD11b+ cells. 
Results shown are from three mice, two-way ANOVA was used to compare both cultures at each 
time-point. Results displayed as mean +/− SD, * p < 0.05, ** p < 0.01. 
 
Figure 4. The phenotype of Gr-1hi and GR-1int cells from GM-CSF and GM-CSF + IL-4 derived BM 
cultures is consistent with the presence of MDSCs. Live cells from GM-CSF derived BM culture were 
characterized on day 3. Cells generated from BM with GM-CSF (10 ng/mL) (solid line) or GM-CSF (10 
ng/mL) + IL-4 (5 ng/mL) (dotted line) were characterized with a panel of phenotypic markers, 
chemokine receptors and activation markers. The shaded grey area represents unstained control cells. 
Results shown are representative of three mice. 
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3.3. Functional Activation and Cytokine Secretion in Early GM-CSF Derived BM Cultures upon LPS 
Stimulation 
Next, it was examined whether the DCs generated in early GM-CSF cultures would be fully 
functional upon TLR stimulation at this early stage of development. To assess this, cells derived from 
GM-CSF BM cultures were stimulated on day 3 with the TLR4 agonist LPS for 24 h and expression of 
surface activation markers on the different cell subsets was analyzed by flow cytometry. Day 3 DCs 
generally expressed lower levels of the co-stimulatory marker CD80 compared to cells stimulated on 
days 4 or 5 of culture. However, day 3 DCs were able to up-regulate expression of activation markers 
such as CD80 from 0.68% ± 0.42 to 19.67% ± 0.84, CD86 from 10.25% ± 0.73 to 70.53% ± 4.14, and 
MHCII from 5.27% ± 0.19 to 20.67% ± 2.07 (Figure 5A). This up-regulation was similar to the 
percentage on day 4 (CD80, from 7.11% ± 1.33 to 25.97% ± 7.47; CD86, from 10.3% ± 2.35 to 51.2% ± 
10.19; MHCII, from 8.91% ± 0.94 to 17.33% ± 5.65) and 5 (CD80, from 9.52% ± 0.72 to 38.7% ± 9.88; 
CD86, from 14% ± 2.77 to 69.5% ± 8.61; MHCII, from 12.87% ± 0.68 to 24.57% ± 4.05) DCs upon LPS 
stimulation (Figure 5A). This suggests that these early DCs are readily activated upon stimulation 
despite their relatively immature phenotype. Sheng et al., have also demonstrated that by day 6, DCs 
stimulated with zymosan (TLR2) or LPS (TLR4) could not reach the same level of activation marker 
expression (MFI) induced on DCs stimulated after three days in GM-CSF cultures [25]. GM-CSF 
derived DCs were further compared with DCs from GM-CSF + IL-4 cultures. It was noted that GM-
CSF + IL-4 DCs upregulated CD80, CD86 and MHCII upon LPS stimulation. Furthermore, GM-CSF 
+ IL-4 DCs expressed 41.17% ± 5.01 CD80, 40.67% ± 12.21 CD86 and 34.3% ± 5.72 MHCII (Figure 5B), 
which was higher than the GM-CSF derived DCs. However, co-stimulatory marker expression 
decreased over time in GM-CSF + IL-4 cultures, regardless if they were stimulated or not (Figure 5B). 
Whilst LPS stimulation significantly up-regulated expression levels, it did not restore them to the 
same expression levels observed on day 3 (Figure 5). Furthermore, co-stimulatory and activation 
marker expression on MDSCs (both Gr-1hi and Gr-1int) was minimally altered following stimulation 
with LPS on days 3–5 (Supplementary Figure S3). 
 
Figure 5. Expression of activation markers after stimulation with the TLR4 ligand LPS on DCs from 
early GM-CSF +/- IL-4 cultures. Day 3 to 5 DCs were stimulated with LPS for 24 h. The expression of 
CD80, CD86 and MHCII on (A) GM-CSF and (B) GM-CSF + IL-4 derived DCs were measured using 
flow cytometry. Results shown are from 3 mice. Two-way ANOVA was used to compare both 
experimental conditions at each time-point. Results displayed as mean +/− SD. * p < 0.05, ** p < 0.01, 
*** p < 0.001. 
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Additionally, the cytokine secretion (IL-6, IL-10, CCL2 (MCP-1), TNF) from supernatants of day 
3 and 4 GM-CSF derived cultures that were stimulated with LPS for 24 h were analyzed using a CBA. 
Large increases in the secretion of pro-inflammatory IL-6 (day 3, 15,042.44 pg/mL ± 2171.45; day 4, 
21,103.06 pg/mL ± 7872.14) and TNF (day 3, 8661.14 pg/mL ± 1319.9; day 4, 8533.87 pg/mL ± 1560.76) 
were measured, as well as the anti-inflammatory cytokine IL-10 (day 3, 341.39 pg/mL ± 128.97; day 4, 
273.37 pg/mL ± 40.86) (Figure 6). Furthermore, a smaller but significant increase in the chemokine 
CCL2 (day 3, 1450.8 pg/mL ± 509.98; day 4, 659.21 pg/mL ± 554.28) was measured (Figure 6). These 
results confirm that the cells in these early cultures are indeed functional.  
 
Figure 6. Cytokine section in early GM-CSF derived cultures upon LPS stimulation. Day 3 to 5 DCs 
generated from GM-CSF derived BM cultures were stimulated with LPS for 24 h. Culture 
supernatants were harvested after 24 h and CBA was used to measure the cytokine secretions within 
the culture, (A) IL-6, (B) IL-10, (C) CCL2, (D) TNF. Results shown are from three mice. Student’s t-
Test was used to compare non-stimulated to LPS stimulated cultures. Results displayed as mean +/− 
SD. ** p < 0.01, *** p < 0.001. 
3.4. Early DCs Stimulate T Cells upon TLR4 Stimulation 
To examine whether DCs and MDSCs harvested from the early cultures were able to induce T 
cells, a hallmark property of mature DCs, a mixed lymphocyte reaction (MLR) was used. Firstly, cells 
of day 3 or 4 GM-CSF or GM-CSF + IL-4 cultures were stimulated with LPS (1 μg/mL), or left 
unstimulated, for 24 h. They were then harvested and sorted for CD11c+ Gr-1- (DCs), CD11c- CD11b+ 
Gr-1hi and CD11c- CD11b+ Gr-1int (MDSCs) populations. Additionally, allogeneic T cells from the 
spleen of BALB/c mice were enriched using MACS® columns. The sorted cells were then co-incubated 
with the enriched T cells (1 DCs: 30 T cells ratio) for a further 72 h and proliferation was assessed 
using CFSE staining (each cell division is indicated by a dilution of the CFSE dye). Early stage DCs 
from non-stimulated (NS) GM-CSF cultures induced T cell proliferation (Figure 7A, first panel), yet 
the Gr-1hi and Gr-1int MDSC populations did not (Figure 7B,C, first panel). Further investigation 
revealed that early GM-CSF derived DCs stimulated by LPS slightly increased their capacity to 
induce T cell proliferation (Figure 7A, second panel). Early MDSCs stimulated with LPS did not 
change, even decreased, their capacity to induce T cell proliferation (Figure 7B,C, second panel). 
Similar observations were detected with the GM-CSF + IL-4 derived DCs and MDSCs, where the GM-
CSF + IL-4 DCs induced the greatest T cell proliferation, following LPS stimulation (Figure 7A, fourth 
panel). These results indicate that early GM-CSF derived DCs are capable of stimulating T cell 
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proliferation, consistent with their heightened stimulatory phenotype following LPS stimulation. 
Conversely, the diminished ability of MDSCs to induce T cell proliferation is consistent with their 
lack of a stimulatory phenotype (Supplementary Figure S3).  
  
Figure 7. Early DCs, but not MDSCs, from both GM-CSF and GM-CSF + IL-4 cultures, induce T cell 
proliferation following LPS stimulation. Cells from day 4 GM-CSF derived BM cultures were sorted 
with a FACS Aria cell sorter into (A) DCs, (B) Gr-1hi MDSCs and (C) Gr-1int MDSCs. These cells were 
either un-stimulated or pre-stimulated with LPS for 24 h before incubation with T cells for 3 days at 
a ratio of 1:30 (DC: T cells). T cell proliferation was measured by CFSE. The shaded grey area 
represents the CFSE positive control. Numbers within the histograms depict percentage of cells 
proliferated. Histograms are representative of three mice. 
3.5. The Addition of LPS Enhances the Ability of Early MDSCs to Co-Stimualte T Cell Proliferation, in the 
Presence of Anti-CD3 and Anti-CD28 
As expected, DCs had a superior ability to induce T cell proliferation to MDSCs, which are 
known to have a suppressive role. To assess the ability of MDSCs to induce T cell proliferation in the 
presence of an added stimulus, and the effect of LPS on this function, cells of day 3 GM-CSF or GM-
CSF + IL-4 cultures were stimulated, or not, with LPS (1 μg/mL) for 24 h. The cells were then harvested 
and sorted for Gr-1hi and Gr-1int MDSCs, as well as CD11c+ DCs using FACS. Additionally, allogeneic 
T cells from the spleen of BALB/c mice were enriched using MACS® columns and co-incubated with 
the sorted DCs, as above, though in the presence of anti-CD3 and anti-CD28 (to stimulate T cells), for 
72 h. The number of T cell divisions, in response to co-stimulation of anti-CD3/CD28 and either DCs 
or MDSCs was measured. Results showed that early MDSCs, particularly GM-CSF derived Gr-1int 
MDSCs, do not co-stimulate T cells as readily as GM-CSF derived GR-1hi MDSCs and DCs (Figure 
8A-C, first panels, 8D).  
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Figure 8. DCs and GR-1hi MDSCs, but not GR-1int MDSCs unless LPS stimulated, from both GM-CSF 
and GM-CSF + IL-4 cultures, co-stimulate T cell proliferation. Cells from day 4 GM-CSF derived 
C57BL/6 BM cultures were sorted with a FACS Aria cell sorter into (A) DCs, (B) Gr-1hi MDSCs and 
(C) Gr-1int MDSCs. These cells were either un-stimulated or pre-stimulated with LPS for 24 h before 
incubation with BALB/c T cells for 3 days at a ratio of 1:30 (DC: T cells) with the addition of anti-CD3 
and anti-CD28 monoclonal antibodies (5 μg/mL each). T cell proliferation was measured by CFSE 
proliferation. The shaded grey area represents the CFSE positive control. Numbers within the 
histograms depict percentage of cells proliferated. Histograms are representative of two to three mice. 
(D) represents mean percentage of CFSE proliferation +/− SD of 2–3 mice. * p < 0.05, ** p < 0.01, *** p < 
0.001. 
Pre-treatment with LPS enhanced the co-stimulatory capacity of GM-CSF derived GR-1int 
MDSCs, to the levels of GR-1hi MDSCs and DCs (Figure 8A-C, second panels, 8D). Interestingly, all 
GM-CSF + IL-4 derived cell subsets stimulated lower levels of T cell proliferation. The lowest levels 
of T cell co-stimulation in GM-CSF + IL-4 derived cells were observed with the GR-1int MDSCs (Figure 
8C, third panel, 8D). Again, pre-treatment with LPS was able to enhance the co-stimulatory capacity 
of GR-1int MDSCs, comparable to GR-1hi MDSCs, but not to the level of DCs (Figure 8A–D). Whereas 
DCs and GR-1hi MDSCs were able to strongly co-stimulate T cells in the presence of anti-CD3 and 
anti-CD28, GR-1int cells displayed reduced co-stimulatory capacity and required an additional signal, 
D 
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i.e., LPS treatment, to acquire their co-stimulatory ability. These data suggest that the GM-CSF and 
GM-CSF + IL-4 derived MDSC subsets are fully functional in the early day 3-4 cultures. 
3.6. Differential Uptake Capacity by Early GM-CSF Derived DCs and MDSCs 
To assess another important function of DCs, endocytic capacity, cells from day 3, 4 and 5 GM-
CSF derived BM cultures were incubated with fluorescent nanoparticles of two different sizes, 40 nm 
or 500 nm (to mimic small and larger pathogens, respectively), for one hour and uptake was assessed 
by flow cytometry. Both 40 nm and 500 nm fluorescent particles were taken up by GM-CSF derived 
DCs (Figure 9A). However, there was a significant decrease in the uptake of 40 nm fluorescent 
particles on day 4 and 5 (44.57% ± 4.18, 24.2% ± 4.88, 8.83% ± 2.22 on days 3, 4 and 5, respectively) 
(Figure 9A), suggesting that their endocytic capacity decreases as these DCs mature. Interestingly, 
uptake of 500 nm fluorescent particles by DCs remained constant throughout day 3 (76.57% ± 2.82), 
4 (76.23% ± 0.75) and 5 (77.1% ± 3.74) (Figure 9A).  
In contrast, uptake of 40 nm particles was minimally detected in Gr-1hi MDSCs (0.13% ± 0.007, 
0.14% ± 0.005, 0.06% ± 0.02 on days 3, 4 and 5, respectively), and Gr-1int MDSCs, where a very small 
percentage of cells tested positive for uptake of 40 nm particles (0.35% ± 0.01, 0.94% ± 0.15, 0.48% ± 
0.04 on days 3, 4 and 5, respectively), though no significant changes were observed over time (Figure 
9B). Both Gr-1hi and Gr-1int MDSCs were able to ingest 500 nm particles efficiently (Figure 9B). Unlike 
DCs, the capacity of MDSCs to take up 500 nm particles was significantly reduced in cells from day 
4 (11.39 ± 1.52 and 15.83% ± 2.14 for Gr-1hi and Gr-1int MDSCs, respectively) and day 5 (6.09% ± 1.24 
and 13.27% ± 2.9 for Gr-1hi and Gr-1int MDSCs, respectively) cultures when compared to cells from 
day 3 cultures (35.37% ± 0.91 and 37.67% ± 3.47 for Gr-1hi and Gr-1int MDSCs, respectively) (Figure 
9B,C). 
 
Figure 9. Differential uptake capacity of DCs and MDSCs in early GM-CSF and GM-CSF + IL-4 
derived cultures. Day 3, 4 and 5 GM-CSF and GM-CSF + IL-4 derived BM cultures were incubated 
with 40 nm or 500 nm particles for one hour at 37 degrees °C in 5% humid CO2 atmosphere. Cells 
were harvested on respective days and endocytic capacity was analyzed by flow cytometry for both 
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40 nm and 500 nm particle uptake by (A,D) DCs, (B,E) Gr-1hi MDSCs and (C,F) Gr-1int MDSCs. Results 
are shown from three mice. One-way ANOVA was used to calculate statistical significance. Results 
displayed as mean +/− SD. * p < 0.05, ** p < 0.01, *** p < 0.001. 
Similar results were seen when analyzing the uptake capacity of early DCs and MDSCs from 
GM-CSF + IL-4 derived BM cultures. In contrast to GM-CSF only cultures, where 44.57% ± 4.81 of 
early DCs had taken up 40 nm particles, only 4.84% ± 1.05 of early DCs derived from GM-CSF + IL-4 
cultures tested positive for 40nm bead uptake on day 3 (Figure 9D). The uptake did not significantly 
change in DCs from day 4 and 5 cultures (Figure 9D). Furthermore, a small, but not significant, 
reduction in the uptake of 500 nm particles was observed for DCs on day 4 and 5 when compared to 
day 3 cultures (Figure 9D). Both Gr-1hi and Gr-1int MDSCs derived from GM-CSF + IL-4 cultures 
showed minimal uptake of 40 nm particles in a very small proportion of cells from day 3 (1.21% ± 
0.83 and 1.06% ± 0.79, respectively), day 4 (0.04% ± 0.005 and 0.08% ± 0.03, respectively) and day 5 
(0.22% ± 0.32 and 0.27% ± 0.37, respectively) cultures (Figure 9E). Similarly to their GM-CSF derived 
counterparts, Gr-1hi and Gr-1int MDSCs derived from GM-CSF + IL-4 cultures were able to take up 500 
nm particles (50.67% ± 9.98 and 42.7% ± 9.44 on day 3, respectively, Figure 9E,F) and, furthermore, 
their capacity to take up these particles decreased over time (26.4% ± 5.68 and 26.4% ± 4.25 on day 4, 
11.4% ± 7.15 and 14.66% ± 7.7 on day 5, respectively) (Figure 9E,F). 
4. Discussion 
DCs are renowned for their potent antigen-presentation properties and have been extensively 
studied over the last decade as targets in immunotherapies and vaccines [26–28]. Given many studies 
on DCs and most DC immunotherapies use GM-CSF derived culture systems, it is of interest to 
understand the characteristics of these types of cultures further. Most studies generate DCs in vitro 
from human peripheral blood or murine BM. They are often generated using GM-CSF alone or with 
a mixture of additional cytokines such as IL-4, and additional maturation agents such as IL-6, TNF, 
IFN-γ or TLR agonists for a period of time if using for immunotherapies [10,20,29]. Such extended 
cultures can increase the yield of DCs with a mature phenotype, which is ideal for inducing an 
immune response [20,29]. The current study has shown that the crucial period for DC generation 
occurs between day 3 and 4 in GMCSF derived cultures using cells that are derived from HSCs. These 
early GM-CSF DCs displayed a conventional DC phenotype (B220-CD4-CD8-CD11b+CD11c+) and 
expressed lower levels of co-stimulatory molecules when compared to later-stage DCs (> day 4) or 
GM-CSF + IL-4 derived DCs. In addition, they were capable of upregulating co-stimulatory molecules 
and activating T cells upon stimulation with LPS, as well as displaying functional endocytic capacity. 
These data show that early GM-CSF derived DCs display the important properties of their more 
mature counterparts and thus may present an interesting target for immunotherapies. Although GM-
CSF is primarily used to generate in vitro DCs, these cultures do not only contain the desired DCs, 
but also other myeloid cell types [14,30].  
In recent studies, GM-CSF has been shown to generate a suppressive myeloid cell subset, 
MDSCs [2–4]. MDSCs are a mixture of early myeloid progenitors, such as immature granulocytes, 
macrophages, and DCs [2,3]. Their phenotype and functions have been studied in detail only more 
recently [31,32]. Whilst some studies use CD11b+, GR-1+ phenotype to describe MDSCs in different 
disease models [33–35], others define granulocytic MDSCs as Ly6Ghi and monocytic MDSCs as 
Ly6Chi [36,37]. Here it is shown that GR-1hi MDSCs are morphologically granulocytic, confirmed by 
their expression of Ly6G, and GR-1int MDSCs are monocytic like cells morphologically and express 
high levels of Ly6C. This is consistent with other reports of GR-1 and Ly6C/G expression [37,38]. 
MDSCs are potent suppressor cells, and their presence in various pathological conditions has been 
proven to cause damaging effects and worsen prognosis in patients [39]. The present data show that 
MDSCs are generated in vitro alongside early DCs in the GM-CSF and GM-CSF + IL-4 cultures. Early 
MDSCs do not have the same ability to stimulate T cells, compared to DCs. Though it has also been 
shown that these early MDSCs are functional in terms of their ability to co-stimulate T cell 
proliferation in the presence of anti-CD3 and anti-CD28, but not without this extra signal. 
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Interestingly, this effect of GR-1int MDSCs could be enhanced upon LPS stimulation. Whether this 
ability is correlated with their suppressive capacity is yet unknown.  
Previous studies have shown that early MDSCs lose their anti-inflammatory state in septic mice 
[40]. Additionally, TLR stimulation has been shown to block the suppressive effects of MDSCs in 
tumor-bearing mice [41], indicating that MyD88 signaling may play a role in the abrogation of the 
suppressive effects of MDSCs. Similarly, Greifenberg et al., analyzed in vitro GM-CSF cultures 
stimulated with LPS and IFN-γ and showed a higher level of nitric oxide production [42]. Stimulation 
with LPS diminished the T cell suppressive capacity in the culture [42]. Interestingly, in their study 
they assessed in vivo MDSC populations and found two splenic populations (Gr-1+, CD11b+ cells) 
that have MDSC phenotypes and a capacity to suppress T cells in vitro [42]. Bunt et al., analyzed 
blood MDSCs from mice with mammary tumors, which induces an inflammatory environment, and 
found that in the presence of IFN-γ and LPS, the mice produced more IL-10 and increased expression 
of CD14 on MDSCs, which was TLR4 dependent [43]. Others have assessed the influence of 
chemotherapy (Paclitaxel) on GM-CSF cultures, and observed that low level paclitaxel did not 
interfere with their generation, instead it increased DC numbers in the culture, though in a TLR4 
independent manner [44]. Hong et al. described the importance of MyD88 in MDSC-induced 
NADPH oxidase and arginase-1 production [45]. MyD88 knockout MDSCs failed to induce 
suppression in tumor-bearing mice, which resulted in an immunogenic response, followed by a 
significant reduction in tumor mass [45]. This suggests that with the use of appropriate conditions to 
grow the DCs used for a vaccine or immunotherapeutic treatment, it might be possible to reduce or 
eliminate the suppressive effects of MDSCs and ensure that the early DCs are sufficiently activated 
to stimulate a potent T cell response.  
In future it would be important to not only assess MDSCs T cell suppressive ability, but also 
measure the production of cytokines (i.e., IL-10) and analyze the levels of arginase 1 and ROS and 
NO production in the cultures. Whilst the present study has not examined the cytokine profile of cells 
derived from GM-CSF + IL-4 cultures, similar studies have shown TNF-α and IL-12p70 secretion in 
rat BM cultures of both GM-CSF and GM-CSF + IL-4 cultures [46]. Additionally, upon stimulation 
with LPS, both cytokines were increased more in GM-CSF + IL-4, compared to GM-CSF alone, 
cultures [46]. Future studies comparing these cultures should expand the panel of cytokines 
analyzed, both with and without LPS stimulation. Other cells in the culture may also contribute to 
the cytokine profile, therefore future studies may also look for the presence of F4/80+ macrophages. 
As these cells are strongly adherent (not collected for the above study) [15], they were not expected 
to be present in high numbers in this study.  
Furthermore, this study investigated the endocytic capacity of early DCs and MDSCs generated 
from GM-CSF derived BM cultures. The initial endocytic capacity of the GM-CSF derived early DCs 
and MDSCs was assessed by incubating with 40 nm and 500 nm particles for one hour and noted that 
the early DCs could take up 40 nm and 500 nm particles. However, the uptake ability of the 40 nm 
particles decreased over two days of maturation, whereas uptake of 500 nm particles was maintained. 
Previous studies have shown that BM derived DCs take up 40 nm particles utilizing the caveolar 
endocytic pathway, whereas 500 nm nanoparticles are taken up by phagocytosis [47]. Extending the 
incubation time to 24 h for the particles with the cells showed a small but significant difference in the 
40 nm and 500 nm particle uptake in DCs over time (data not shown). This suggests that while these 
early DCs are capable of taking up particles of both sizes, it is their rate of uptake of 40 nm particles 
that is affected as they mature. This was further confirmed by the fact that early GM-CSF + IL-4 
derived DCs (the mature equivalent of GM-CSF derived DCs) did not effectively take up 40 nm 
particles after one hour of incubation. Other studies have shown that immature DCs have higher 
endocytic capacity and that maturation has a specific downregulation effect on phagocytosis and 
macropinocytosis [48,49]. Interestingly, these studies also showed that DC maturation did not affect 
uptake of nanoparticles by certain mechanisms, such as receptor mediated endocytosis [48,49]. The 
heterogeneity in DC subsets and type of activating signal may also influence the phagocytic ability 
of DCs, with CD40 ligand-activated cells retaining phagocytic and presentation capabilities, though 
these processes were diminished in LPS-activated cells [50]. 
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When the uptake of MDSCs was investigated, the data showed that both MDSC subsets 
preferred 500 nm particles, although some cells took up 40 nm particles. This was consistent with 
early MDSCs derived from both GM-CSF and GM-CSF + IL-4 cultures. Both cultures showed a similar 
trend of a decrease in uptake of the 500 nm particles over time, which suggests that MDSCs generated 
from both GM-CSF cultures and GM-CSF + IL-4 cultures are similar in terms of maturity and function. 
Given the distinct preferences in particle size uptake by early DCs and MDSCs, it suggests different 
kinetics of endocytosis in the different cell types. Future studies would benefit from analyzing the 
influence of LPS stimulation on endocytosis in both DC and MDSC populations. 
5. Conclusions 
Taken together, the data presented here reveal information on the type of cells and their function 
in early GM-CSF derived BM cultures. This may have additional potential value for early GM-CSF-
derived DCs for their use in vaccine models and immunotherapies. Further investigation is required 
to fully comprehend and effectively manipulate these cultured cells. The data discussed show that 
cells harvested from early GM-CSF (as well as GM-CSF + IL-4) derived BM cultures yield functional 
DCs and MDSCs, which are useful tools to study maturation, activation and T cell stimulation 
capabilities, as well as endocytic capacity, within these cultures. Given their higher endocytic 
capacity, early DCs may also be a promising candidate for future immunotherapies, though much 
more research would be needed to confirm this direction.  
Supplementary Materials: The following are available online at www.mdpi.com/2076-393X/8/3/522/s1, Figure 
S1: Morphology of early stage DCs and MDSCs. Morphology of sorted cell populations; CD11c+ resembling 
DCs, Gr-1hicells resembling granulocytes (termed, granulocytic MDSCs); Gr-1int cells resembling monocytes 
(termed monocytic MDSCs), Figure S2: Expression of Ly6C and Ly6G on CD11b+, GR-1+ MDSCs. BM cells were 
cultured with GM-CSF for 3 days and phenotype of CD11c-, CD11b+, GR-1+ MDSCs assessed by flow cytometry. 
(A) Percentage of CD11c-, CD11b+ cells that are GR-1hi and GR-1int. (B) MFI of Ly6G and Ly6C on GR-1hi and 
GR-1int cells. GR-1hi cells express both Ly6G and Ly6C, whereas GR-1int cells only express Ly6C. (C). 
Representative histograms of Ly6C and Ly6G with GR-1hi and Gr-1int overlays. n = 2 mice, Figure S3: Expression 
of co-stimulatory markers on early (D3–5) GM-CSF derived MDSCs upon LPS stimulation. Day 3–5 GM-CSF 
derived BM MDSCs were stimulated with LPS for 24 h prior to harvesting. The expression of the maturation and 
activation markers CD40, CD80, CD86 and MHCII were analyzed using flow cytometry. The shaded grey area 
represents unstained control cells, solid black line represents unstimulated cells and dotted black line represents 
cells stimulated with LPS. Results shown are representative dot plots of three mice. 
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